FINANCIAL STATEMENT RESTATEMENT (Details 1) - USD ($)	3 Months Ended						9 Months Ended
	Jul. 31, 2025	Apr. 30, 2025	Jan. 31, 2025	Jul. 31, 2024	Apr. 30, 2024	Jan. 31, 2024	Jul. 31, 2025	Jul. 31, 2024
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Beginning Additional Paid-in Capital - Balance at October 31, 2023			$ 43,611,365				$ 43,611,365
Beginning Accumulated Deficit - Balance at October 31, 2023			(45,434,694)				(45,434,694)
Net loss for the nine months ended July 31, 2024	$ (498,010)	$ (470,066)	$ (5,461,393)	$ (495,584)	$ (570,855)	$ (507,073)	(6,429,469)	$ (1,573,512)
Ending Additional paid in capital - Balance at July 31, 2024	50,204,960						50,204,960
Ending Accumulated Deficit - Balance at July 31, 2024	$ (51,864,163)						$ (51,864,163)
Previously Reported [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Beginning Additional Paid-in Capital - Balance at October 31, 2023				41,291,591		41,079,902		41,079,902
Beginning Accumulated Deficit - Balance at October 31, 2023				(42,697,762)		(41,609,945)		(41,609,945)
Beginning Total Stockholders' Deficit - Balance at October 31, 2023				$ (920,868)		(92,201)		$ (92,201)
Series A preferred issued pursuant to patent agreement, shares				10,000,000				10,000,000
Series A preferred issued pursuant to patent agreement, amount				$ 10,000				$ 10,000
Net loss for the nine months ended July 31, 2024				(496,621)				1,584,438
Ending Additional paid in capital - Balance at July 31, 2024				41,784,933	41,291,591			41,784,933
Ending Accumulated Deficit - Balance at July 31, 2024				(43,194,383)	(42,697,762)			(43,194,383)
Ending Total Stockholders' Deficit - Balance at July 31, 2024				(984,711)	(920,868)			(984,711)
Revision of Prior Period, Adjustment [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Beginning Additional Paid-in Capital - Balance at October 31, 2023				390,275		390,275		390,275
Beginning Accumulated Deficit - Balance at October 31, 2023				(476,270)		(486,159)		(486,159)
Beginning Total Stockholders' Deficit - Balance at October 31, 2023				$ (90,995)		(100,884)		$ (100,884)
Series A preferred issued pursuant to patent agreement, shares				(5,000,000)				(5,000,000)
Series A preferred issued pursuant to patent agreement, amount				$ (5,000)				$ (5,000)
Net loss for the nine months ended July 31, 2024				1,037				(10,926)
Ending Additional paid in capital - Balance at July 31, 2024				390,275	390,275			390,275
Ending Accumulated Deficit - Balance at July 31, 2024				(475,233)	(476,270)			(475,233)
Ending Total Stockholders' Deficit - Balance at July 31, 2024				(89,958)	(90,995)			(89,958)
As Restated [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Beginning Additional Paid-in Capital - Balance at October 31, 2023				41,681,866		41,470,177		41,470,177
Beginning Accumulated Deficit - Balance at October 31, 2023				(43,174,032)		(42,096,104)		(42,096,104)
Beginning Total Stockholders' Deficit - Balance at October 31, 2023				$ (1,011,863)		$ (193,085)		$ (193,085)
Series A preferred issued pursuant to patent agreement, shares				5,000,000				5,000,000
Series A preferred issued pursuant to patent agreement, amount				$ 5,000				$ 5,000
Net loss for the nine months ended July 31, 2024				(495,584)				1,573,512
Ending Additional paid in capital - Balance at July 31, 2024				42,175,208	41,681,866			42,175,208
Ending Accumulated Deficit - Balance at July 31, 2024				(43,669,616)	(43,174,032)			(43,669,616)
Ending Total Stockholders' Deficit - Balance at July 31, 2024				$ (1,074,669)	$ (1,011,863)			$ (1,074,669)